Therapeutics
15 Results were found on Technologies
Sub Category Name
Synthetic 9-cis beta Carotene for treatment of retinal degeneration
9-cis β-carotene-rich is an effective treatment for retinal diseases. Its production in algae was a bottleneck of clinical trials. Now there is a new a synthetic method for its production. BACKGROUNDAge related macular degeneration (AMD) and Retinitis pigmentosa (RP) are a leading cause of vision incapacitation and blindness worldwide (>30 million people). In recent clinical […] Read More >
Novel Specific Disease-Modifying PERK Activator for Huntington’s Disease
The need: There is no efficient therapy at present for Huntington’s disease (HD) nor for any other neurodegenerative disease, including Alzheimer’s and Parkinson’s diseases. No disease-modifying approaches exist. • Gene therapy-based clinical trials have failed so far, highlighting the need for other approaches. These include the recent interruption of antisense oligonucleotide clinical trials for HD. Background […] Read More >
Improved Calcitonin-based Therapeutics
TechnologyThe aggregation site on human calcitonin has been identified, paving the way for development of specific inhibitors of calcitonin amyloid fibril formation. Such inhibitors will enable development of improved calcitonin therapeutics as well as greatly facilitate in vitro calcitonin manipulations. The NeedThe therapeutic use of human calcitonin is severely limited by its tendency to associate […] Read More >
MiRacle: Revolutionizing Disease Diagnostics with MicroRNA
MiRacle is a groundbreaking startup focused on transforming disease diagnostics using microRNA analysis. Our innovative method offers a non-invasive, cost-effective, and highly accurate solution for early-stage disease detection. By leveraging our proprietary technology, we aim to revolutionize the field of diagnostics and save countless lives. Problem: Accurate diagnosis is a prerequisite for efficient health care. […] Read More >
Homocysteine fibrillar assemblies display crosstalk with Alzheimer’s disease amyloid polypeptide
High levels of homocysteine (Hcy) are reported as a risk factor for Alzheimer’s disease (AD). Correspondingly, inborn hyperhomocysteinemia is associated with an increased predisposition to the development of dementia in later stages of life. Furthermore, despite the apparent association between protein aggregation and AD, attempts to develop a therapy that targets explicitly this process have […] Read More >
